歐康維視生物-B(01477.HK)公佈中期業績 收入增長162.1% 經調整研發支出達1.99億元
格隆匯8月26日丨歐康維視生物-B(01477.HK)公吿，截至2022年6月30日止六個月，公司收入增加至人民幣5450萬元，較2021年同期所得收入增長162.1%。該增加乃主要歸因於(i)眼科產品(即歐沁、酒石酸溴莫尼定滴眼液、優施瑩及康姝)的銷售額穩步增長，主要是由於公司在中國醫院營銷及推廣該產品的工作進展順利；(ii)適利達及適利加等藥品在醫院渠道推廣服務收入增長，及(iii)有關埃美丁及貝特舒的以銷售為基礎的特許權使用費收入增加。
截至2022年6月30日止六個月，公司錄得經調整虧損淨額人民幣7690萬元(非國際財務報吿準則調整)，較截至2021年6月30日止六個月的人民幣1.09億元減少了人民幣3230萬元，乃主要歸因於(i)毛利增加，此乃主要由於眼科產品銷售、醫藥產品推廣服務產生的收入及以銷售為基礎的特許權使用費收入的增加；及(ii)得益於有效的外幣風險管理措施，公司於報吿期內取得匯兑淨收益較去年同期大幅增加。
截至2022年6月30日止六個月，公司的經調整研發支出(非國際財務報吿準則調整)為人民幣1.99億元，較截至2021年6月30日止六個月的人民幣2.445億元減少18.7%。該減少主要由於報吿期內並無與授權引進產品有關的重大前期付款被資本化，而截至2021年6月30日止六個月，公司則根據日期為2021年4月13日的獨家許可協議向Alimera支付前期付款1000萬美元，由於該授權產品已經滿足資本化標準，該筆款項被進一步資本化。
截至本公吿日期，公司各研發管線產品進展順利。截至2022年6月30日，公司已擁有24種藥物資產，建立起全面及覆蓋眼前及眼後段疾病的眼科藥物管線，其中7種管線藥物已處於III期臨牀試驗階段，10款產品處於商業化階段，令公司在國內眼科業界取得領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
